Results 1 to 10 of about 22,947 (145)

Acute Promyelocytic Leukemia Presenting With a Myeloid Sarcoma of the Spine: A Case Report and Literature Review

Frontiers in Oncology, 2022
Myeloid sarcoma is a rare extramedullary tumor of immature myeloid cells. Certain known acute myeloid leukemia cytogenetic abnormalities, in particular t(8,21), has been associated with a higher incidence.
Xuemei Shu, Qiuling Wu, Tao Guo, Hua Yin, Jingdi Liu   +4 more
doaj   +1 more source

Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia. [PDF]

PLoS ONE, 2016
AIM:All-trans retinoic acid combined to anthracycline-based chemotherapy is the standard regimen of acute promyelocytic leukemia. The advent of arsenic trioxide has contributed to improve the anti-leukemic efficacy in acute promyelocytic leukemia.
Ye Zhang, SiJing Wu, Dan Luo, JianFeng Zhou, DengJu Li   +4 more
doaj   +1 more source

Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism

Haematologica, 2020
Obesity correlates with hematologic malignancies including leukemias, but risk of specific leukemia subtypes like acute promyelocytic leukemia and underlying molecular mechanisms are poorly understood.
Luca Mazzarella, Edoardo Botteri, Anthony Matthews, Elena Gatti, Davide Di Salvatore, Vincenzo Bagnardi, Massimo Breccia, Pau Montesinos, Teresa Bernal, Cristina Gil, Timothy J Ley, Miguel Sanz, Krishnan Bhaskaran, Francesco Lo Coco, Pier Giuseppe Pelicci   +14 more
doaj   +1 more source

Treatment of Central Nervous System Relapse in Acute Promyelocytic Leukemia by Venetoclax: A Case Report

Frontiers in Oncology, 2021
Extramedullary relapse of acute promyelocytic leukemia is a rare phenomenon and is associated with a poor prognosis, with the central nervous system being the most common site of relapse. The current treatments are still limited.
Xuzhao Zhang, Jinliang Chen, Weiqin Wang, Xian Li, Yanbin Tan, Xiaohong Zhang, Wenbin Qian   +6 more
doaj   +1 more source

SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA DEVELOPED AFTER TREATMENT OF NON-HODGKIN'S LYMPHOMA. CLINICAL CASE AND REVIEW OF LITERATURE.

Arta Medica, 2020
Background: Acute promyelocytic leukemia is an acute myeloid leukemia that accounts approximately 10% of acute myeloid leukemia cases. Acute promyelocytic leukemias usually appears as a de novo finding.
Victor Tomacinschii, Maria Robu, Vasile Musteață, Irina Mocanu, Sanda Buruiană, Natalia Sporîș, Veronica Feghiu   +6 more
doaj   +1 more source

The CEBPA gene is down-regulated in acute promyelocytic leukemia and its upstream promoter, but not the core promoter, is highly methylated

Haematologica, 2011
Impairment of CCAAT Enhancer Binding Protein alpha (CEBPA) function is a common finding in acute myeloid leukemia; nevertheless, its relevance for acute promyelocytic leukemia pathogenesis is unclear.
Bárbara Amélia Santana-Lemos, Ana Paula Alencar de Lima Lange, Mariana Tereza de Lira Benício, Thiago Donizete da Silva José, Antônio Roberto Lucena-Araújo, Alexandre Krause, Carolina Hassibe Thomé, Eduardo Magalhães Rego   +7 more
doaj   +1 more source

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group

Haematologica, 2018
In standard-risk acute promyelocytic leukemia, recent results have shown that all-trans retinoic acid plus arsenic trioxide combinations are at least as effective as classical all-trans retinoic acid plus anthracycline-based chemotherapy while being less
Lionel Adès, Xavier Thomas, Agnes Guerci Bresler, Emmanuel Raffoux, Olivier Spertini, Norbert Vey, Tony Marchand, Christian Récher, Arnaud Pigneux, Stephane Girault, Eric Deconinck, Claude Gardin, Olivier Tournilhac, Jean Francois Lambert, Patrice Chevallier, Stephane de Botton, Julie Lejeune, Hervé Dombret, Sylvie Chevret, Pierre Fenaux   +19 more
doaj   +1 more source

Acute promyelocytic leukemia with increased bone marrow reticulin fibrosis: Description of three cases and review of the literature

Hematology/Oncology and Stem Cell Therapy, 2018
Pathologic increase in bone marrow reticulin fibrosis can be present in many malignant hematopoietic diseases. In acute leukemia, one-third of patients have some degree of marrow reticulin fibrosis at presentation, which is thought to be related to ...
Iman Abou Dalle, Samer Nassif, Ali Bazarbachi   +2 more
doaj   +1 more source

The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia

Haematologica, 2008
Background The gene for preferentially expressed antigen of melanoma (PRAME) has been shown to be over-expressed in acute promyelocytic leukemia, but its actual incidence and clinical impact are still unknown.Design and Methods We studied PRAME ...
Carlos Santamaría, María Carmen Chillón, Ramón García-Sanz, Ana Balanzategui, María Eugenia Sarasquete, Miguel Alcoceba, Fernando Ramos, Teresa Bernal, José Antonio Queizán, María Jesús Peñarrubia, Pilar Giraldo, Jesús F. San Miguel, Marcos Gonzalez   +12 more
doaj   +1 more source

Efficacy and the Adverse Effects of Oral Versus Intravenous Arsenic for Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized-Controlled Studies

Technology in Cancer Research & Treatment, 2020
Acute promyelocytic leukemia, a subtype of acute myeloid leukemia, is highly curable. In subgroup of patients with non-high-risk acute promyelocytic leukemia, intravenous arsenic trioxide plus all-trans-retinoic acid is considered the preferred regimen ...
Natthaporn Sasijareonrat MD, Nikolaus Jahn MD, Patompong Ungprasert MD, MS, Weerapat Owattanapanich MD   +3 more
doaj   +1 more source